In this article, we are going to take a look at where Corcept Therapeutics Incorporated (NASDAQ:CORT) stands against other ...

Corcept Therapeutics CORT has outperformed the market over the past 5 years by 23.49% on an annualized basis producing an ...

We recently published a list of Billionaire Jim Simons’ RenTech’s 10 Small-Cap Stock Picks with Huge Upside Potential. In ...

Cort Guitars announced a new multi-scale, seven string guitar in the KX507 series – the KX507MS Pale Moon - on Tuesday. "The ...

Biopharma company Corcept Therapeutics (NASDAQ:CORT) will be reporting earnings tomorrow after the bell. Here’s what to ...

CORT) stands against other best performing healthcare stocks to buy now. On April 15, CNBC reported that President Trump’s healthcare-focused executive order brought in a win for the sector.

Corcept is developing its lead candidate, relacorilant, for treating patients with Cushing’s syndrome. In December 2024, CORT submitted a new drug application (NDA) for relacorilant to the FDA ...

In fact, the analyst believes that Corcept Therapeutics Incorporated’s (NASDAQ:CORT) current weakness presents an attractive buying opportunity as its Korlym product is expected to see ...